AI Article Synopsis
- 18 F-FAPI-42 PET/CT is a new imaging method designed to target fibroblast activation protein (FAP), which is important for identifying certain heart conditions.
- In a case study involving a 50-year-old man with chest tightness, the imaging revealed abnormal uptake at the apex of the left ventricle, indicating the presence of a left ventricular mural thrombus.
- The lack of uptake of another imaging substance, 18 F-FDG, suggests that the abnormal findings with 18 F-FAPI-42 could be clinically significant and warrant further evaluation.
Article Abstract
18 F-FAPI-42 PET/CT is a novel imaging tool targeting fibroblast activation protein (FAP). We describe the 18 F-FAPI-42 PET/CT findings of a left ventricular mural thrombus in a 50-year-old man who had chest tightness. The 18 F-FAPI-42 PET/CT showed annular uptake at the apex of the left ventricle, but there was no uptake of 18 F-FDG. This case showed that abnormal 18 F-FAPI-42 uptake in the heart may be associated with mural thrombus and should be evaluated clinically.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RLU.0000000000005051 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preclinical and First-In-Human Imaging of Novel [F]F-FAPI-FUSCC-07 Tracer: Comparative Prospective Study with [F]F-FAPI-42 and [F]F-FAPI-74.
Mol Pharm
January 2025
Department of Nuclear Medicine, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
This study aimed to develop and evaluate a novel fibroblast activation protein (FAP)-specific tracer, fluorine-18-labeled fibroblast activation protein inhibitor-FUSCC-07 ([F]F-FAPI-FUSCC-07), for use in both preclinical and clinical settings. Preclinical evaluations were conducted to assess the stability and partition coefficient of [F]F-FAPI-FUSCC-07. Experiments involving human glioma U87MG cells demonstrated its cellular uptake and inhibitory properties.
View Article and Find Full Text PDFF-FAPI-42 PET/CT for preoperatively identifying intrahepatic cholangiocarcinoma and hepatocellular carcinoma.
Quant Imaging Med Surg
January 2025
Department of Nuclear Medicine, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Background: Accurately differentiating hepatocellular carcinoma (HCC) from intrahepatic cholangiocarcinoma (ICC) is essential for therapeutic decision-making. This study aimed to explore the value of Fluor 18 (F)-conjugated fibroblast-activation protein inhibitor (FAPI-42) positron emission tomography-computed tomography (PET/CT) in distinguishing HCC from ICC preoperatively.
Methods: Patients with suspected intrahepatic lesions who underwent F-FAPI-42 PET/CT were retrospectively assessed and placed into an HCC group and an ICC group based on postoperative pathology.
F-FAPI-42 PET/CT and F-FDG PET/CT in Patients with Malignant Digestive System Neoplasms: A Head-to-Head Comparative Study.
Mol Imaging Biol
January 2025
Department of Nuclear Medicine, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, China.
Purpose: Radionuclide-labeled fibroblast activation protein inhibitor (FAPI) is an emerging tumor tracer. We sought to assess the uptake and diagnostic performance of F-FAPI-42 PET/CT compared with simultaneous 2-deoxy-2[F]fluoro-D-glucose (F-FDG) PET/CT in primary and metastatic lesions in patients with malignant digestive system neoplasms and to determine the potential clinical benefit.
Procedures: Forty-two patients (men = 30, women = 12, mean age = 56.
[F]F-FAPI-42 PET dynamic imaging characteristics and multiparametric quantification of lung cancer: an exploratory study using uEXPLORER PET/CT.
Eur J Nucl Med Mol Imaging
January 2025
Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University, 1838 Guangzhou North Road, Guangzhou, China.
Purpose: To explore the dynamic and parametric characteristics of [F]F-FAPI-42 PET/CT in lung cancers.
Methods: Nineteen participants with newly diagnosed lung cancer underwent 60-min dynamic [F]F-FAPI-42 PET/CT. Time-activity curves (TAC) were generated for tumors and normal organs, with kinetic parameters (K, K, K, K, K) calculated.
F-FAPI-42 PET/CT enhances the diagnostic efficacy for peritoneal metastasis of colorectal cancer and guides treatment decisions: an original retrospective study.
Gastroenterol Rep (Oxf)
December 2024
Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.
Background: Colorectal cancer is the third-most common type of cancer. When peritoneal metastasis (PM) develops, diagnosing metastatic lesions is difficult and the prognosis is poor. This study aimed to compare the value of fluorine-18 fibroblast activation protein-specific inhibitor (F-FAPI-42) and fluorine-18 fluorodeoxyglucose (F-FDG) positron emission tomography/computed tomography (PET/CT) for detecting PM of colorectal cancer and to guide clinical decision-making.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!